ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Newellis Inc

Newellis Inc (NUWE)

0.249249
0.02925
(13.30%)
Closed May 26 4:00PM
0.26
0.01075
(4.31%)
After Hours: 7:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.26
Bid
0.252
Ask
0.26
Volume
5,593,594
0.2201 Day's Range 0.275
0.125 52 Week Range 3.83
Market Cap
Previous Close
0.22
Open
0.2201
Last Trade Time
Financial Volume
$ 1,398,963
VWAP
0.250101
Average Volume (3m)
5,974,727
Shares Outstanding
6,801,443
Dividend Yield
-
PE Ratio
-1.59
Earnings Per Share (EPS)
-3.33
Revenue
8.86M
Net Profit
-22.63M

About Newellis Inc

Nuwellis Inc is a medical device company. Its solutions include Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidne... Nuwellis Inc is a medical device company. Its solutions include Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flow, automatically displaying real-time data to the medical staff. Show more

Sector
Electromedical Apparatus
Industry
Electromedical Apparatus
Headquarters
Wilmington, Delaware, USA
Founded
1970
Newellis Inc is listed in the Electromedical Apparatus sector of the NASDAQ with ticker NUWE. The last closing price for Newellis was $0.22. Over the last year, Newellis shares have traded in a share price range of $ 0.125 to $ 3.83.

Newellis currently has 6,801,443 shares outstanding. The market capitalization of Newellis is $35.91 million. Newellis has a price to earnings ratio (PE ratio) of -1.59.

NUWE Latest News

Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida

MINNEAPOLIS, May 14, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the...

Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy

MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced a new...

Nuwellis, Inc. Announces First Quarter 2024 Financial Results

MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported...

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

MINNEAPOLIS, May 02, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today...

Nuwellis Announces Closing of $2.7 Million Public Offering

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid...

Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) --  Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.04-13.33333333330.30.3190.20626191830.25123512CS
40.100162.60162601630.15990.360.125156430910.23671252CS
12-0.3106-54.43392919730.57060.63010.12559747270.24757067CS
26-0.35-57.37704918030.610.890.12533251660.30020709CS
52-2.64-91.03448275862.93.830.12517718270.41326327CS
156-392.74-99.93384223923935390.125148198645.69466679CS
260-528.32-99.9508116085528.585390.125144873246.48549364CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

NUWE Discussion

View Posts
The Night Stalker The Night Stalker 2 days ago
nic3e
👍️0
The Night Stalker The Night Stalker 1 week ago
starting
👍️0
db101 db101 1 week ago
As the overall market starts to drop… NUWE will thrive
👍️0
Holtzi Holtzi 2 weeks ago
I predict Im getting back in today :)
👍️0
db101 db101 2 weeks ago
Any predictions?
👍️0
Holtzi Holtzi 3 weeks ago
I guess Im not a fan of issuing shares and doing RS approx every 2 years to comply w/ NASDAQ
Thi s year is the RS Year. per May 1, 2024 Proxy Statement
👍️0
BurgerKing82 BurgerKing82 3 weeks ago
Keep an eye on this one?
👍️0
Zardiw Zardiw 3 weeks ago
$NUWE Chart from #DDAmanda - #1 Stock Screener :

Find Winners Early:



Z
👍️0
The Night Stalker The Night Stalker 3 weeks ago
nice
👍️ 1
Holtzi Holtzi 3 weeks ago
GOT OUT AT .3 TODAY BUT PLAN TO GET BACK IN AROUND .18??
👍️0
INV4 INV4 3 weeks ago
Nuwellis, Inc. Announces First Quarter 2024 Financial ResultsNuwellis, Inc. Announces First Quarter 2024 Financial Results

Tue, May 7, 2024

https://finance.yahoo.com/news/nuwellis-inc-announces-first-quarter-120000903.html?guccounter=1&guce_referrer=aHR0cHM6Ly9kdWNrZHVja2dvLmNvbS8&guce_referrer_sig=AQAAABkXGl5nBDowplt7CUUbnRUbIEc9EdIJlYjwIvUTd0W2SVIKw0x9u__QaWxT8qI2-1mWxP8TPhc_mrpMBZoxJ0jklwvHpVt9C2gbJGOmKuaFtdP3Y7VwFSDB-lVwbcgF32mMwpFAAL-oukC9_f-Zolhy9jT5SPRD51AnFXe6vWxR

$NUWE
👍️0
Invest-in-America Invest-in-America 3 weeks ago
NUWE: No "don't blink' today???
👍️0
Awl416 Awl416 3 weeks ago
Hold on
👍️0
trendzone trendzone 3 weeks ago
Once again the corrupt small hedge funds show up the next day on small stocks, that had run ups the past day, and turn on their grind down machines programs after they shorted the previous days highs, and profit off the scared little fliptards who sell out with their profits getting cut over night,if you want to beat the small wall street criminal hedge funds, you have to not be a wimp and sell out,and raise sell orders much higher,and let the scm bags get squeezed out of their corrupt short manipulation positions.
👍️0
Holtzi Holtzi 3 weeks ago
Im in at .15 - think Im gonna hold until .50... Not sure yet
👍️0
GhosTraderX GhosTraderX 3 weeks ago
Solid Day here, more to come...

Bought in at 0.18

Should test 0.30+

GhosT
👍️0
Holtzi Holtzi 3 weeks ago
holding until Monday EOD I think
👍️0
INV4 INV4 3 weeks ago
Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

May 02, 2024

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its innovative pediatric Continuous Renal Replacement Therapy (CRRT) device branded Vivian™. This patent strengthens Nuwellis' intellectual property portfolio and paves the way for the development of novel technology designed to improve treatment options for critically ill children.
The patented technology focuses on a design feature that allows healthcare providers to switch seamlessly between stationary operation and “transport” or “ambulation” mode, enabling unprecedented patient mobility. This innovative feature offers unmatched flexibility, allowing clinicians to tailor treatment plans to the specific needs of each young patient.

"We are thrilled to receive this patent allowance from the USPTO," said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis. “A core focus of our business strategy is developing novel technology and a strong IP portfolio. This innovative technology will empower healthcare providers with the ability to adapt treatment plans as needed, ultimately leading to improved patient care and outcomes for critically ill children and neonates.”

Nuwellis is currently developing a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. This development effort is funded in part by a $1.7 million grant from the National Institutes of Health (NIH). The company has partnered with Minneapolis-based research and development firm Koronis Biomedical Technologies Corporation (KBT), the grant recipient, in the design and development of a custom pediatric product that will enable clinicians to better care for babies with limited kidney function.

Nuwellis is committed to developing life-saving technologies specifically designed for the unique needs of pediatric patients. This patent allowance represents a significant advancement in the company's mission to revolutionize pediatric fluid management.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.

About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

https://ih.advfn.com/stock-market/NASDAQ/newellis-NUWE/stock-news/93767856/nuwellis-receives-uspto-notice-of-patent-allowance

$NUWE
👍️0
Jane1999 Jane1999 3 weeks ago
I am holding for tomorrow
👍️0
Holtzi Holtzi 3 weeks ago
Flippers and profit takers. Ill guess 3 of these as this stedy climbs untill financials, guessing other news will follow the report
👍️0
Holtzi Holtzi 3 weeks ago
Guessing a better report than was anticipated??
👍️0
Holtzi Holtzi 3 weeks ago
Anyone have an exit price in mind??
👍️0
Holtzi Holtzi 3 weeks ago
hoping for a good report EOW
👍️0
Holtzi Holtzi 3 weeks ago
NICE PRE MARKET TRADING AND GOOD NEWS
👍️0
Awl416 Awl416 3 weeks ago
Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology
👍️0
Holtzi Holtzi 4 weeks ago
Ill bite.... Im in
👍️0
Awl416 Awl416 1 month ago
Whoops
👍️0
Monksdream Monksdream 1 month ago
NUWE new 52 lo
👍️0
Monksdream Monksdream 3 months ago
NUWE 10Q due March 5
👍️0
db101 db101 3 months ago
As of today… NUWE has 5,000,000 shares of stock outstanding
👍️0
db101 db101 3 months ago
Sounds good 1 hot toddy…
👍️0
db101 db101 3 months ago
With today’s closing @.7011… NUWE is a BUY
👍️0
1hot toddy 1hot toddy 3 months ago
man r they big spenders. employees get 764 shares each at option price of todays close 70 cents. vesting at 25% a year. only 3 mil shares issued but that can always change. few more days like today and all shares will be held.
👍️0
db101 db101 3 months ago
NUWE is a HOLD @.5325…
👍️0
1hot toddy 1hot toddy 4 months ago
WOOOOW 27000 SHARE BUY $$$$$$$$$$$$$
👍️0
theswordman theswordman 4 months ago
HELLO darlin'
👍️0
1hot toddy 1hot toddy 5 months ago
12000 SHARE BUY RIGHT NOW $$$$$$$$$$$$$$$
👍️0
1hot toddy 1hot toddy 5 months ago
16000 AND 10K SHARE BUY $$$$$$$$$$$$$$$$$$$$
👍️0
db101 db101 5 months ago
@.69… NUWE is now listed as a HOLD
👍️0
db101 db101 5 months ago
EGR… 19%
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 6 months ago
$NUWE > New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients

Nuwellis, Inc.
Tue, November 28, 2023 at 2:00 PM GMT+1

Recommendation Rating: Buy


Nuwellis, Inc.
The data demonstrate that the hematocrit sensor within the Nuwellis Aquadex® system offers unique advantages for fluid overloaded small patients

MINNEAPOLIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- New real-world data demonstrate that pediatric patients with fluid overload respond well to Aquadex® ultrafiltration therapy with continuous hematocrit monitoring, announced Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload. The publication, “Using Aquapheresis with Continuous Hematocrit Monitoring to Guide Ultrafiltration,” was featured in Pediatric Nephrology. 1

The publication is a single-center case study review of pediatric patients with hypoalbuminemia and severe fluid overload. Patients were treated with Nuwellis’ Aquadex® ultrafiltration therapy with continuous hematocrit monitoring to guide isotonic fluid removal. The study concluded that the therapy successfully treated small patients without hemodynamic instability or other complications, demonstrating that Aquadex is an effective treatment option for fluid overload.

“We’re proud to share new evidence supporting the clinical need and applications for Aquadex among pediatric patients, and we’re grateful to Dr. Michelle Starr and her colleagues for their trust and confidence in our therapy,” said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis. “Our proprietary hematocrit sensor which is incorporated into the Aquadex console was a result of physician feedback and observations from clinical studies that drove us to make our Aquadex therapy even smarter. Our team is committed to supporting diuretic-resistant patients broadly, and I’m encouraged to see data validating this strategy as Nuwellis works to expand access to ultrafiltration to even more patients and clinicians.”

“Managing fluid overload for pediatric patients can be challenging, but these new data and our growing library of evidence support our view that Aquadex can provide a safe and effective method for restoring fluid balance,” said John Jefferies, MD, Chief Medical Officer of Nuwellis. “The continuous hematocrit monitoring function within the Aquadex provides unique and proprietary therapeutic direction, as demonstrated in this important publication.”

Effectively managing fluid overload for pediatric patients is critical. Fluid overload is associated with significant increases in mortality in pediatric patients. Research has shown that a 3% increase in mortality is observed for every 1% increase in fluid overload among these patients. 2,3

Aquadex is proven to simply, safely, and precisely remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics. Providers can specify and adjust the rate of fluid removed for each individual patient, resulting in a gradual reduction of excess fluid. The device’s built-in, customizable hematocrit monitoring technology provides real-time measurement of percent blood volume changes that can be tailored to individual patients’ needs. A customizable fluid removal rate is particularly important for pediatric patients, who have a small amount of blood in their bodies. The Aquadex system is cleared by the FDA for use in adults and pediatric patients weighing 20 kg (44 lbs.) or more.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.

About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.


CONTACTS:

Investors:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com

Media:
Laurel Hood
Health+Commerce
laurel@healthandcommerce.com

Link: https://finance.yahoo.com/news/real-world-data-highlight-clinical-130000845.html

$$$NUWE$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 6 months ago
$NUWE ~ Nuwellis Inc
@0.65
+ 0.0227 (+3.62%)
Volume: 991,510
Day Range: 0.60 - 0.7658
Last Trade Time: 6:05:39 PM EST


$$$NUWE$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 6 months ago
$NUWE >>> Know what you own! O/S @3.25M only.

https://www.nuwellis.com/corporate/
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 6 months ago
$NUWE >>> CTB @554.19%!
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 6 months ago
$NUWE took me a starter @.64! ;)


ULTRALOWFLOATER!! $$$$$$$
👍️0
Monksdream Monksdream 6 months ago
NUWE new 52 week low
👍️0
db101 db101 7 months ago
EGR… 17%
👍️0
Monksdream Monksdream 8 months ago
NUWE new 52 week low
👍️0
SusieQutie SusieQutie 8 months ago
Could this be turning around now? Have we hit bottom? Pilot program with DaVita was supposed to begin by the end of the third quarter. Would love to see an update from $NUWE on this. Dipped my toes in @ $1.60. Any good news should move this back up over $2.
👍️0
db101 db101 9 months ago
…the chart is looking promising
👍️0

Your Recent History

Delayed Upgrade Clock